By Tushar Patel Vice President, US Sleep-Wake Commercial and Global Strategic Marketing, Neurology Business Group Each March, many Americans look forward to advancing our clocks by one hour as...

Ivan Cheung, Chairman, Eisai Inc. and Global President, Neurology Business Group, Eisai Co., Ltd. & Harald Hampel, MD, PhD, Vice President, Chief Medical Officer, Neurology Business Group, Eisai Inc.

By Renee Campbell, MD, MBA, MPH, Global Value and Access Epilepsy and Sleep lead, Genevieve De Sousa Meier, Executive Director, Head of Global Value and Access, and Amir Abbas Tahami Monfared,...

By Feride Frech, PhD, MPH, Senior Director, US HEOR & RWE, Eisai Inc, and Timothy Juday, Director, US HEOR & RWE, Eisai Inc. Insomnia, the most common sleep-wake disorder, is prevalent in the...

Harald Hampel, MD, PhD Vice President, Chief Medical Officer, Neurology Business Group, Eisai Inc. Alzheimer’s disease (AD) is a devastating neurodegenerative disease. It is estimated to affect...

By Jeff Somers, For years, the treatment of Alzheimer’s disease focused on symptoms. New research targets the pathophysiological changes underneath — with potentially promising results....

Though many people with insomnia go into doctor’s visits expecting a drug to relieve their sleeplessness, stakeholders are moving increasingly toward holistic approaches. Clinicians, medical...

It is no surprise that sleep problems are on the rise due to life changes caused by the coronavirus disease 2019 (COVID-19) pandemic. Based on my experience, the current environment, with myriad...

Dr. Lynn Kramer, CMO, Eisai Neurology, discusses the FDA’s regulatory pathway allowing for the extrapolation of clinical data from adjunctive to monotherapy use in partial-onset seizures, which improves access to epilepsy treatments.

Human genetics is transforming the way new drugs are discovered, giving unprecedented hope for delivering better medicines